Mechanism of Fructus Lycii against dry eye: an analysis based on network pharmacology and experimental verification
10.3980/j.issn.1672-5123.2023.5.05
- VernacularTitle:基于网络药理学及实验验证探讨枸杞子治疗干眼的作用机制
- Author:
Yu-Xue MU
1
;
Ming-Zhuang HU
1
;
Dong-Yu WEI
1
;
Xin-Yue XU
1
;
Ling-Xuan YAOLI
1
;
Zuo-Ming ZHANG
1
;
Tao CHEN
1
Author Information
1. Aerospace Clinical Medical Center, School of Aerospace Medicine, Air Force Medical University, Xi'an 710032, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
Fructus Lycii;
dry eye;
network pharmacology;
AKT1;
IL-6;
tumor necrosis factor-α
- From:
International Eye Science
2023;23(5):738-746
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the mechanism of fructus lycii in treating dry eye based on network pharmacology and experimental verification.METHODS: Taking “fructus lycii” as key words, the active ingredients and target of fructus lycii were searched by using Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). Gene targets related to dry eye(DE)were searched by GeneCards and OMIM databases. The target genes of fructus lycii and DE were imported into Venn software to obtain the intersection target map of them. After that, the data were imported into the String database to obtain the PPI protein-protein interaction network diagram. Using Cytoscape3.7.2 software, the PPI protein-protein interaction network diagram was constructed for active ingredients, target sites and related diseases of fructus lycii. The Bioconductor platform and R language were used for gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analysis. And the key targets in the pathogenesis of DE were verified by experiments.RESULTS: Through TCMSP, 45 types of effective chemical components of fructus lycii, 174 target genes corresponding to active components and 131 common target genes with DE were screenedout. In accordance with the network topology of “drug-composition-disease-target”, 27 main effective components of fructus lycii were found in the treatment of DE. The PPI network was analyzed according to the high degree value, which is the key targets of fructus lycii for DE treatment, mainly including AKT1, VEGFA, CASP3, IL1B, JUN, PTGS2, CXCL8, etc. According to GO enrichment analysis, 166 biological functions and processes of fructus lycii for DE treatment were obtained. KEGG enrichment analysis showed that 31 signaling pathways were involved. Additionally, experimental verification displayed that the protein expressions of AKT1, interleukin-6(IL-6), tumor necrosis factor(TNF-α)and IL-17 in conjunctiva tissue of the DE model group were significantly increased.CONCLUSIONS: Through network pharmacology, this study confirmed that the treatment of DE by fructus lycii is a complex process involving multi-components, multi-targets and multi-pathways, and that the treatment of DE by fructus lycii is mainly regulated by anti-inflammatory and apoptosis-related molecules.
